Intellia Therapeutics Inc Stock News

Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, have tumbled in 2022.

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2022 Results Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate

- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts - New data

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St

The risks are formidable, but the chances of a massive gain are too much to pass up.

NTLA offers investors a unique opportunity to buy into an up-and-coming biotech company with impressive clinical data and the potential for future growth. Management continues executing their plan to

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics

Exchange-traded fund (ETF) manager Cathie Wood made headlines this week after she announced that she would cede control of her role as portfolio manager for the 3D Printing ETF (BATS: PRNT ) and the�

It's been a difficult year for Cathie Wood stocks and exchange-traded funds, as the ARK Innovation ETF (NYSEARCA: ARKK ) has lost over 50% of its market capitalization. The losses have been driven by

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

Shares of Intellia Therapeutics Inc. NTLA, +7.36% gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. REGN, +1.18% announced positive data from an ongoing P

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. The update could send CRISPR stocks flying.